At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 269 enrolled
Drug / intervention
CD07805/47 Gel +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
In Brief
A Phase 2 clinical trial evaluating CD07805/47 Gel and Vehicle Gel for Rosacea. Completed, enrolled 269 participants across 20 sites.
Detailed Summary
The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema associated with rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedAug 2010
Primary CompletionDec 2010
Study CompletionJan 2011
TodayJul 2026
First PostedAug 3, 2010
Enrollment StartAug 1, 2010
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.9 years ago
Interventions
CD07805/47 Geldrug
CD07805/47 Gel 0.5% QD
Vehicle Geldrug
Vehicle Gel QD
CD07805/47 Geldrug
CD07805/47 Gel 0.18% QD
CD07805/47 Geldrug
CD07805/47 Gel 0.18% BID
Vehicle Geldrug
Vehicle Gel BID